+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emerging Therapeutic Targets and Drug Delivery Approaches in IBD. Advances in Pharmacology Volume 101

  • Book

  • December 2024
  • Elsevier Science and Technology
  • ID: 5994732
Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapters on timely topics, including Fibrosis in IBD - AXL as a Promising Therapeutic Target, Developing a pathway to test anti-fibrotic drugs in Crohn’s disease, Emerging therapeutics for the management of intestinal fibrosis and strictures, GCPII for IBD, Fistulas/stem cell products for IBD/Crohn’s, The landscape of new therapeutic opportunities for IBD, TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis, Dectin-1 as a therapeutic target for IBD, and more.

Additional sections cover BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases, Scripps - S1P, The potential of targeting TREM-1 in Inflammatory Bowel Disease, and Microbiome therapies.

Table of Contents

1. Fibrosis in IBD AXL as a Promising Therapeutic Target
Calen Steiner and P Higgins
2. Developing a pathway to test anti-fibrotic drugs in Crohn’s disease
Florian Rieder
3. Emerging therapeutics for the management of intestinal fibrosis and strictures
Laura Ensign and Florin M. Selaru
4. GCPII for IBD
Diane E. Peters
5. Fistulas/stem cell products for IBD/Crohn’s
Hai-Quan Mao
6. The landscape of new therapeutic opportunities for IBD
Andres Hurtado-Lorenzo and Jennifer L. Swantek
7. TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis
Stephan Targan
8. Dectin-1 as a therapeutic target for IBD
Xiaolei Zhu
9. BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases
Jia Zhou
10. Scripps S1P
Hugh Rosen
11. The potential of targeting TREM-1 in Inflammatory Bowel Disease
Marc Derive
12. Microbiome therapies
Christopher Burton Ford